Item 6. Exhibits
8K characters. Original on sec.gov ·
Item 6. Exhibits
(a) Exhibits
| Exhibit Number | Description | |||||||
| 10.1 | Award agreement and related notice of grant in connection with the 2026 grant of performance restricted stock units (the "2026 PSUs") to Leonard S. Schleifer, M.D., Ph.D. (Incorporated by reference from the Form 8-K for Regeneron Pharmaceuticals, Inc. (the "Registrant"), filed September 30, 2026.) | |||||||
| 10.2 | Award agreement and related notice of grant in connection with the grant of the 2026 PSUs to George D. Yancopoulos, M.D., Ph.D. (Incorporated by reference from the Form 8-K for the Registrant, filed September 30, 2026.) | |||||||
| 10.3* | Form of restricted stock purchase agreement in connection with the grant of equity in Three Sevens Holding Corp. to each of Leonard S. Schleifer, M.D., Ph.D. and George D. Yancopoulos, M.D., Ph.D. | |||||||
| 10.4** | Sixth Amendment to Amended and Restated License and Collaboration Agreement, dated as of October 1, 2026, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi. | |||||||
| 19.1 | Insider Trading Policy. | |||||||
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. | |||||||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. | |||||||
| 32 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350. | |||||||
| 101 | Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the Registrant's Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025; (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2026 and 2025; (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2026 and 2025; (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025; and (v) the notes to the Registrant's Condensed Consolidated Financial Statements. | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |||||||
| * Certain of the exhibits and/or schedules to this Exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules of this Exhibit to the SEC upon its request. | ||||||||
| ** Certain confidential portions of this Exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of all confidential portions of this Exhibit that were omitted to the SEC upon its request. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| REGENERON PHARMACEUTICALS, INC. | |||||||||||||||||
| Date: | October 30, 2026 | By: | /s/ Christopher Fenimore | ||||||||||||||
| Christopher Fenimore | |||||||||||||||||
| Executive Vice President, Finance and | |||||||||||||||||
| Chief Financial Officer | |||||||||||||||||
| (Duly Authorized Officer) |